1st Quarter - Report
BROWN RUDNICK LLP for APOTEX CORPORATION
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT DENNIS FOREMAN New | The Office of U.S. Senator Orrin Hatch, Senior Health Policy Advisor, 1993 to 2001 Centers for Medicare & Medicaid Services (CMS), Director, Office of Legislation and Congressional Affairs, 2001 to 2005 |
| LISA LAYMAN | SPA, Sen. Stabenow (05-07); SPA, Sen Graham(01-04); LA, Sen Bryan(00); LA, Sen Chafee (97-99); CBO, PA(92-96) |
| HENRY W MENN | CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commiss(93-95) |
Health Issues HCR
Implementation of the Biologics Price Competition and Innovation Act (BPCIA); House 21st Century Cures Act Discussion Draft
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT DENNIS FOREMAN New | The Office of U.S. Senator Orrin Hatch, Senior Health Policy Advisor, (1993 to 2001); Centers for Medicare & Medicaid Services (CMS), Director, Office of Legislation and Congressional Affairs, (2001 to 2005) |
| LISA LAYMAN | SPA, Sen. Stabenow (05-07); SPA, Sen Graham(01-04); LA, Sen Bryan(00); LA, Sen Chafee(97-99); CBO, PA(92-96) |
| HENRY W MENN | CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commission (93-95) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.